Mesenchymal stem cell-derived extracellular vesicle therapy in breast cancer: A systematic review and meta-analysis of in vitro studies.
Mussin NM., Zhilisbayeva KR., Baspakova A., Ishimova LA., Kurmanalina MA., Tamadon A.
Meta-analysis, published in Mol Ther Oncol (2025) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Meta-analysis
- Journal
- Mol Ther Oncol (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41510212
- PMCID
- PMC12775850
- DOI
- 10.1016/j.omton.2025.201107
Abstract (original English)
Mesenchymal stem/stromal cell-derived extracellular vesicles (MSC-EVs) have emerged as promising cell-free therapeutics for breast cancer due to their innate tumor tropism and molecular delivery capacity. This systematic review and meta-analysis evaluated the in vitro therapeutic potential and safety of MSC-EVs. A comprehensive search up to July 2025 identified 58 eligible studies. Quantitative data were extracted on cell viability, apoptosis, and migration, along with EV source, cargo, and engineering strategy. Random-effects meta-analyses showed that MSC-EV treatment significantly reduced cancer cell viability (standardized mean difference [SMD] = -4.79), inhibited migration (SMD = -4.70), and increased apoptosis (SMD = +4.16). Effects were consistent across major cell lines (MCF-7, MDA-MB-231, and 4T1) and MSC sources (bone marrow, adipose, and umbilical cord), despite moderate heterogeneity (I 2 = 50%-70%). Notably, unmodified bone marrow MSC-EVs carrying miR-23b were associated with dormancy induction in vivo , whereas engineered EVs loaded with therapeutic miRNAs or drugs and modified with targeting ligands demonstrated improved specificity and efficacy. Precision engineering of MSC-EVs can enhance antitumor activity but requires stringent cargo control to avoid dormancy risks. Only in vitro data were quantitatively analyzed, while in vivo findings were discussed for mech
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.